Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients

NCT02324803 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

86

Enrollment

OTHER

Sponsor class

Conditions

Self Efficacy
Adverse Drug Event
Carcinoma, Renal Cell

Interventions

DRUG: pazopanib

Sponsor

Southern China Urology Cancer Consortium